声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。全球制药巨头辉瑞/代码PFE在2024年第四季度业绩报告披露了关于ADC候选新药 12 亿美元的无形资产减值费用:10亿美元涉及终止B7-H4的ADC felmetatug vedotin 。另外 2 亿美元的减值费用与Disitamab vedotin...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.